Research programme: viral infections and cancer VLP vaccines - TechnoVax

Drug Profile

Research programme: viral infections and cancer VLP vaccines - TechnoVax

Alternative Names: Cancer vaccine - TechnoVax; Dengue vaccine - TechnoVax; HIV vaccine - TechnoVax; Inhaled powder influenza VLP vaccine - TechnoVax; Inhaled powder RSV VLP vaccine - TechnoVax; Pandemic influenza vaccine - TechnoVax; Respiratory syncytial virus (RSV) VLP vaccine - TechnoVax; Seasonal tetravalent influenza VLP vaccine - TechnoVax; Universal influenza vaccine - TechnoVax; Virus-like particle (VLP) vaccines - TechnoVax; Zika virus vaccine - TechnoVax; ZIKA VLP vaccine - TechnoVax

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TechnoVax
  • Developer City University of New York; TechnoVax
  • Class AIDS vaccines; Cancer vaccines; Dengue vaccines; Influenza A vaccines; Influenza virus vaccines; Virus-like particle vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Dengue; Influenza virus infections; Parainfluenza virus infections; Respiratory syncytial virus infections; Zika virus infection
  • Research HIV infections

Most Recent Events

  • 09 May 2017 Preclinical trials in Zika virus infection in USA (Parenteral)
  • 09 May 2017 Adverse events and immunogenicity data from a preclinical study in Zika virus infection released by TechnoVax
  • 02 Jun 2014 TechnoVax receives a one-year SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAD) for a VLP-based Respiratory Syncytial Virus vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top